Desidustat tablets, which mimics the human body's response to low oxygen availability at high altitudes, will be studied for Covid-19 management for the first time.
Pankaj R Patel, chairman of Zydus Cadila, said his company is stepping up efforts to fight Covid-19 through therapeutic drugs, diagnostics and vaccines. "With Desidustat we will study a novel approach for management of Covid-19," Patel said.
Zydus had initiated two Phase III trials of Desidustat. One is being conducted in 588 patients not on dialysis and another on 392 patients on dialysis.